Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa News Currents.
Press releases published on August 19, 2025

Outsourced CFO announces FundRaise Conference to help South African founders close capital in 2025
One-night forum with founders, investors, and finance experts on 28 August 2025, Wesgro Auditorium, Cape Town. Sponsored by Business Partners. CAPE TOWN, SOUTH AFRICA, August 19, 2025 /EINPresswire.com/ -- Outsourced CFO (OCFO), in conjunction with …

BitMobile and Twytch Partner to Empower South African Drivers Through Blockchain Innovation, VR Training, and Phēnix X
JOHANNESBURG, SOUTH AFRICA, August 19, 2025 /EINPresswire.com/ -- BitMobile and Twytch Announce Groundbreaking Partnership to Empower South African Drivers Through Blockchain, VR Training, and the Phēnix X Mobile Revolution BitMobile and Twytch Power …

China Top All-In-One Service Manufacturer for Stone Processing Machine Showcased by ShuiNan Machinery at BATIMATEC
QUANZHOU, FUJIAN, CHINA, August 19, 2025 /EINPresswire.com/ -- The construction industry faces a fundamental challenge: finding comprehensive Stone Processing Equipment solutions that combine cutting-edge technology, reliable manufacturing, and complete …

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100
DENVER, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits the LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage …

Silo Pharma’s PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway
SPC-15’s intranasal spray formulation meets safety standards for clinical trial development SARASOTA, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and …

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), …

Ajax Therapeutics Appoints David Waller, PhD, as Senior Vice President and Head of CMC
NEW YORK and CAMBRIDGE, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation Janus Kinase (JAK) inhibitors for patients with myeloproliferative neoplasms, today announced the appointment …

Milestone® Pharmaceuticals to Present at Upcoming Conferences
MONTREAL and CHARLOTTE, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced President and CEO, Joe Oliveto, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, to take place …

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window -First-in-human trial of ALX2004 builds …

Midland Commences an Exploration Program for Copper-Gold-Molybdenum-Silver Occurrences on the Saruman Project
MONTREAL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to report the start of an exploration program to follow up on the 2024 copper-gold-molybdenum-silver (Cu-Au-Mo-Ag) occurrences identified on its Saruman …

Midland débute un programme d’exploration pour les minéralisations en cuivre-or-molybdène-argent sur le projet Saruman
MONTRÉAL, 19 août 2025 (GLOBE NEWSWIRE) -- Exploration Midland inc. (« Midland ») (TSX-V : MD) a le plaisir d’annoncer le commencement d’un programme d’exploration pour faire un suivi sur les minéralisations en cuivre-or-molybdène-argent (Cu-Au-Mo-Ag) …

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage …

Apollo Silver Congratulates Equinox Gold on FAST-41 Permitting
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Apollo Silver Corp. (“Apollo” or the “Company”) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0) congratulates Equinox Gold Corp. (TSX: EQX) (NYSE American: EQX) on the recent acceptance of its Castle …

Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to- …

MEXC Demonstrates Exceptional Financial Strength with Latest Proof of Reserve Showing Bitcoin Reserves at 129.85%
VICTORIA, Seychelles, Aug. 19, 2025 (GLOBE NEWSWIRE) -- MEXC, a leading global cryptocurrency exchange, continues to showcase outstanding financial stability with its latest bi-monthly Proof of Reserve (POR) audit revealing sustained over-collateralization …

MEXC Expands Fiat-to-Crypto Trading Pairs and Launches Fortune Spin Event Offering Rewards up to 1,000 USDT
VICTORIA, Seychelles, Aug. 19, 2025 (GLOBE NEWSWIRE) -- MEXC, a leading global cryptocurrency exchange, has expanded its credit and debit card payment service to support 45 fiat currencies and 34 crypto assets, unlocking 1,374 fiat-to-crypto trading pairs. …

ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals
Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and subgroup analysis from its recent Phase 3 COMPETE trial will be …